Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Complement Ther Med. 2020 Mar;49:102251. doi: 10.1016/j.ctim.2019.102251. Epub 2020 Jan 8.
C-reactive protein (CRP) is considered to be an inflammatory marker in type 2 diabetes (T2D) and it is produced by liver cells. The evidence has suggested that resveratrol has anti-inflammatory effect. This study aimed to evaluate the effect of resveratrol supplementation on CRP level in patients with T2D using a systematic review and meta-analysis of randomized controlled trials.
Electronic databases were completely searched using Medline, ISI Web of Science, EMBASE and Cochrane Library and Scopus until October 2019. Meta-analysis was performed using random-effects model and inverse variance method. Heterogeneity and publication bias were evaluated in selected studies. Sensitivity analyses and prespecified subgroup were conducted to evaluate potential heterogeneity. Meta-regression was performed to assess the effect of potential confounders on the estimated effect sizes.
Six trials comprising a total of 491 subjects were included in this meta-analysis. The results showed significant reduction in the level of CRP [SMD (-0.34 mg/l) (95 % CI, -0.52, to -0.16) p < 0.05] in participants with T2D following supplementation with resveratrol. No significant publication bias was observed in the meta-analysis. Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol supplementation on CRP level in T2D patients were affected by resveratrol dose and duration of resveratrol. Random-effects meta-regression did not indicate any significant association of CRP level with potential confounders including resveratrol dose, duration of treatment, age and gender of type 2 diabetic patients.
We found a significant reduction in CRP level in patients with type 2 diabetes, who received resveratrol supplementation.
C-反应蛋白（CRP）被认为是 2 型糖尿病（T2D）中的炎症标志物，由肝细胞产生。有证据表明白藜芦醇具有抗炎作用。本研究旨在通过对随机对照试验的系统评价和荟萃分析，评估白藜芦醇补充剂对 T2D 患者 CRP 水平的影响。
使用 Medline、ISI Web of Science、EMBASE 和 Cochrane Library 以及 Scopus 等电子数据库进行全面检索，检索时间截至 2019 年 10 月。使用随机效应模型和逆方差法进行荟萃分析。在选定的研究中评估异质性和发表偏倚。进行敏感性分析和预设亚组分析，以评估潜在的异质性。进行荟萃回归分析，以评估潜在混杂因素对估计效应大小的影响。
本荟萃分析纳入了 6 项共涉及 491 名受试者的试验。结果表明，T2D 患者补充白藜芦醇后，CRP 水平显著降低[SMD（-0.34mg/l）（95%CI，-0.52，-0.16），p<0.05]。荟萃分析未观察到显著的发表偏倚。亚组和敏感性分析表明，白藜芦醇补充对 T2D 患者 CRP 水平的综合效应受白藜芦醇剂量和白藜芦醇治疗持续时间的影响。随机效应荟萃回归未表明 CRP 水平与潜在混杂因素（包括白藜芦醇剂量、治疗持续时间、2 型糖尿病患者的年龄和性别）有任何显著关联。
我们发现，接受白藜芦醇补充的 2 型糖尿病患者的 CRP 水平显著降低。
